Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-03-24

FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)

View source ↗

Summary

FDA supplemental approval for Neurontin (gabapentin) by Parke-Davis Division of Pfizer Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NEURONTIN (gabapentin)

Snippet

SUPPL AP for NEURONTIN (GABAPENTIN)